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There is a growing body of evidence linking mitochondrial dysfunction, mediated either through
inherited mitochondrial DNA (mtDNA) variation or mitochondrial proteomic deficit, to Parkinson’s dis-
ease (PD). Yet, despite this, the role of somatic mtDNA point mutations and specifically point-mutational
burden in PD is poorly understood. Here, we take advantage of recent technical and methodological
advances to examine the role of age-related and acquired mtDNA mutation in the largest study of mtDNA
in postmortem PD tissue to date. Our data show that PD patients suffer an increase in mtDNA mutational
burden in, but no limited to, the substantia nigra pars compacta when compared to matched controls.
This mutational burden appears increased in genes encoding cytochrome c oxidase, supportive of pre-
vious protein studies of mitochondrial dysfunction in PD. Accepting experimental limitations, our study
confirms the important role of age-related mtDNA point mutation in the etiology of PD, moreover, by
analyzing 2 distinct brain regions, we are able to show that PD patient brains are more vulnerable to
mtDNA mutation overall.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Mitochondria are critical subcellular organelles, charged with
providing cellular energy (adenosine triphosphate [ATP]) through
oxidative phosphorylation (OXPHOS) by the respiratory chain.
Thirteen of the w90 OXPHOS proteins are encoded in by mito-
chondrial DNA (mtDNA); a highly mutable, maternally inherited,
DNA molecule, which undergoes negligible intermolecular recom-
bination. The breakdown of OXPHOS, a disruption of cellular energy
supply and demand, often leads to disease and is mediated largely
through a purported vicious cycle of reactive oxygen species
dependent mutation formation (de Grey, 2005).
Parkinson’s disease (PD) is the second most common neurode-
generative disorder after Alzheimer’s disease, affecting approxi-
mately 1% of the worldwide elderly population. Pathologically, the
disease is well-characterized as a progressive loss degeneration of
the substantia nigra pars compacta (SNpc), yet, despite extensive
study the causes of PD remain elusive;with<10% of cases caused by
a genetic defect. Multiple lines of evidence implicate mitochondrialGroup, Institute of Genetic
castle upon Tyne, NE1 3BZ,
6.
n).
Inc. This is an open access articledysfunction in the pathogenesis of idiopathic PD, with genetic
analysis focusing largely on the role of extant, inherited, mtDNA
variants (Ghezzi et al., 2005; Hudson et al., 2013, 2014; Latsoudis
et al., 2008). Reports have indicated that isolated mtDNA deletion
formation is important (Bender et al., 2006; Kraytsberg et al., 2006),
but the role of somatic single nucleotide variation has never been
fully investigated in PD.
To assess the role of single nucleotide variants in PD, we used
next generation sequencing (NGS) to analyze the mtDNA from the
SNpc and frontal cortex (FC) of 180 idiopathic PD cases, comparing
mtDNA mutational burden to age-matched asymptomatic control
tissues.
2. Materials and methods
2.1. Cohort
Tissue samples, FC (n ¼ 220) and mid-brain (n ¼ 190), were
obtained from the Newcastle Brain Tissue Resource (NBTR, New-
castle upon Tyne, UK), the Parkinson’s UK Brain Bank (Imperial
College London, London, UK), and the MRC Edinburgh Brain and
Tissue Bank (University of Edinburgh, Edinburgh, UK). Patient
samples (n ¼ 180) were all Caucasian community-based PD cases,
fulfilling UK-PD Society brain bank criteria for the diagnosis of PDunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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et al., 1992). Control samples (n ¼ 40) were all Braak stage <II
(Braak et al., 2003), showing no signs of clinical or neuropatho-
logical PD (M ¼ 22 and F ¼ 18, average age ¼ 77.9 years). Mean
postmortem delay was 14.2 hours (Standard deviation [StDev] ¼
12.2 hours) in cases and 11.6 hours in controls (StDev ¼ 13.4 hours),
with no significant differences between brain banks.
2.2. MtDNA isolation and enrichment
SNpc was micro-dissected at 4 C from whole mid-brain sections
(10  20 mm sections per sample; Hudson et al., 2011), FC samples
were extracted from50e100mg tissue blocks. TomaximizeDNAyield
from limited tissue, total DNA was extracted from 190 SN samples
(150 cases and 40 controls) and 220 FC samples (180 cases and 40
controls) using Qiagen DNA micro kit (Qiagen, Hilden, Germany).
MtDNA was enriched using long-range polymerase chain reac-
tion. To eliminate the potential for error and nuclear DNA
contamination, amplicons were polymerized using PrimeSTAR GXL
DNA polymerase (error rate¼ 0.00108%, Takara Bio, Saint-Germain-
en-Laye, France) in 2 overlapping fragments, using primer set-1:
CCC TCT CTC CTA CTC CTG-F (m.6222e6239) and CAG GTG GTC
AAG TAT TTA TGGeR (m.16133e16,153), and set-2: CAT CTT GCC
CTT CAT TAT TGCeF (m.15295e15,315) and GGC AGG ATA GTT CAG
ACG-R (7773e7791). To avoid run-specific amplification variation,
case and control SN and FC samples were randomly mixed in each
isolation and enrichment experiment. Initially, primer efficiency
and specificity was assessed as successful after zero amplification of
DNA from Rho0 cell lines, avoiding the unintended amplification of
nuclear pseudogenes.
Amplified products were assessed by gel electrophoresis, against
DNAþve and DNAve controls, and quantified using a Qubit 2.0
fluorimeter (Life Technologies, Paisley, UK). Each amplicon was
individually purified using Agencourt AMPure XP beads (Beckman-
Coulter, USA), pooled in equimolar concentrations and requantified.
Successful long-range polymerase chain reaction amplification,
based on quality and final concentration, was successful in 174 SN
(92%) and 209 FC (95%) samples.
2.3. MtDNA sequencing
Pooled amplicons were “tagmented,” amplified, cleaned,
normalized, and pooled into 48 sample multiplexes using the Illu-
mina Nextera XT DNA sample preparation kit (Illumina, CA, USA).
Multiplex pools were sequenced using MiSeq Reagent Kit v3.0
(Illumina, CA, USA) in paired-end, 250 bp reads. To avoid run-
specific variation, case and control SN and FC samples were
randomly mixed in each run. All samples were sequenced across 9
runs, average data output per run¼ 13 Gb (StDev¼ 1.2 Gb), with an
average of 95% > QV30 (StDev ¼ 2.1%). Postrun data, limited to
reads with QV  30, were exported for analysis.
2.4. Bioinformatic analysis
Postrun FASTQ files were analyzed using a bioinformatic pipeline.
Reads were aligned to the revised Cambridge reference sequence
(NC_012920) using BWA v0.7.10 (Li and Durbin, 2009), invoking-
mem (Li and Durbin, 2009). Aligned reads were sorted and
indexed using Samtools v0.1.18 (Li et al., 2009), duplicate reads were
removed using Picard v1.85 (http://broadinstitute.github.io/picard/).
Variant calling (including somatic calling) was performed in tandem
using VarScan v2.3.8 (Koboldt et al., 2009, 2012,) (minimum depth¼
1500, supporting reads ¼ 10, base quality  30, mapping quality 
20, and variant threshold ¼ 1.0%) and LoFreq v0.6.1 (Wilm
et al., 2012). Concordance calling between VarScan and LoFreqwas >99.5%. Concordant variants were annotated using ANNOVAR
v529 (Wang et al., 2010). Perl scripts (available on request) were used
to extract base/read quality data and coverage data. MtDNA hap-
logroup was determined through established algorithms based on
existing phylogenetic data (Torroni et al., 1996; van Oven and Kayser,
2009) and using Haplogrep (Kloss-Brandstatter et al., 2011).
2.5. Post-bioinformatic QC
In total, 383 samples were sequenced; 174 isolated from the SN
(138 cases and 36 controls) and 209 from FC (170 cases and 39
controls). However, to ensure high-quality comparisons, we
invoked strict post-bioinformatic quality control (QC). We removed
samples if coverage was <99% at a minimal depth of 1500 and
removed variants with significant strand biasing (invoked through
VarScan). Final analysis was based on 2 cohorts SN¼ 148 (114 cases,
M ¼ 80/F ¼ 35, and 34 controls, M ¼ 17/F ¼ 17) and FC ¼ 155 (125
cases, M ¼ 82/F ¼ 43, and 30 controls, M ¼ 17/F ¼ 15). Hetero-
plasmic variants are defined as >1% but <99% and homoplasmic
variants are defined as >99%. In addition, low-quality variants,
present in low-complexity regions, were not included in compar-
ative analysis (Goto et al., 2011).
NGS revealed a high level of genetic variability, identifying 727
unique variants in SNpc tissue samples (n ¼ 148) and 788 unique
variants in FC tissue samples (n ¼ 155) (Supplementary Table 1).
The proportion of heteroplasmic variants was significantly different
between SN (30.4%) and FC (43.8%) (p¼ 0.0001). Although higher in
number, the mean comparative macrophage-activating factor
(MAF) of heteroplasmic variants was lower in FC compared to SN
(MAF¼ 0.032 and 0.045, respectively) and the difference was larger
when restricting the variants to heteroplasmic and non-
synonymous (SN-MAF ¼ 0.035 and FC-MAF ¼ 0.020).
The transition/transversion (Ti/Tv) ratio, a hallmark of selection
or randommutation, in humanmtDNA has been estimated as 13.75
(Belle et al., 2005). Analysis of sequence data from SN revealed a
similar value (Ti/Tv¼ 13.54, 8.2% transversions); however, FC tissue
appeared to have a higher frequency of transversions (Ti/Tv ¼ 9.5,
9.5% transversions) although not significantly (p ¼ 7.5  102).
Coding region heteroplasmy (defined as >1%/<99%) was typi-
cally low, predominantly <10% in either SN or FC from both cases
and controls (Supplementary Fig. 1); although variants >10% het-
eroplasmy appeared overrepresented in cases, this trend was not
significant (SN-cases ¼ 17/270 versus controls ¼ 1/47, p ¼ 4.9 
101 and FC-cases ¼ 7/223 versus controls ¼ 1/32, p ¼ 1.00).
Analysis of total DLOOP, rRNA, and tRNA heteroplasmic variation
showed a comparatively higher frequency of heteroplasmic varia-
tion than coding regions, but showed no significant differences
between cases and controls in either SN (DLOOP-P ¼ 6.2  101,
rRNA-P ¼ 1.0  101, and tRNA-P ¼ 2.8  101) or FC (DLOOP-P ¼
5.8 101, rRNA-P¼ 1.1101, and tRNA-P¼ 4.1101). Similarly to
coding region variants, most rRNA and tRNA variations were low
level (<10%) in both SN and FC from both cases and controls; how-
ever, DLOOP variation was notably higher (Supplementary Fig. 3).
2.6. Somatic mutation analysis
In addition to the original QC, sample pairs were also placed
onto the mtDNA phylogeny (www.mitomap). Pairs which did not
have concordant mtDNA haplogroups (n¼ 8) in addition to samples
that failed previous coverage-based QC (n ¼ 9) were removed from
subsequent analysis leaving a final cohort of 103 individuals (84
cases, and 19 controls).
Using FC tissue as ancestral mtDNA reference sequence and
SNpc as the vulnerable, affected, tissue allowed us to identify: “de-
novo variants” (present in SNpc, but not FC); “somatic losses”
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tion, “positive-heteroplasmic shift” indicates a heteroplasmy
increase from FC to SNpc (DhetFC < SNpc) and “negative-hetero-
plasmic shift” indicates heteroplasmy decrease from FC to SNpc
(DhetFC > SNpc).
Somatic analysis revealed a high level of genetic variability,
identifying 1305 differential variants in 103 samples (84 cases and
19 controls). Five hundred fifty-eight were de novo to SNpc, 315
were lost in SNpc, 122 showed an increase in heteroplasmy in SNpc
(DhetFC < SNpc), and 310 showed a decrease in heteroplasmy in
SNpc (DhetFC > SNpc; Supplementary Table 2).
2.7. Codon bias analysis
Whole HumanmtDNA genome data, n¼ 18,114 sequences, were
downloaded from the National Centre for Biotechnology Informa-
tion Nucleotide database (http://www.ncbi.nlm.nih.gov/nuccore/),
using the keyword phrase “Homo [Organism] AND gene_in_mi-
tochondrion[PROP] AND 14000:19,000[SLEN] NOT pseudogene[All
Fields].” Sequences with pathogenic mtDNA variants (available at
www.mitomap.org) were removed (n¼ 458 sequences), non-Homo
sapien sequences were removed (n ¼ 7). Similar to genotype QC,
non-European mtDNA sequences (defined with m.8701A, m.8540T,
and 10873T) were also removed (n ¼ 7051). Finally, truncated
mtDNA sequences (<16,500 bp) were removed (n ¼ 663) leaving a
final data set of n ¼ 9935 sequences. The sequence data set was
aligned using MUSCLE (Edgar, 2004), analyzed using Haplogrep
(Kloss-Brandstatter et al., 2011; van Oven and Kayser, 2009) and
subsequently filtered tomatch the Major European haplogroups (H,
V, J, T, U, K, W, X, I, R, and N) leaving a final sample cohort of n ¼
7729 sequences harboring 2873 variants. Codon usage was calcu-
lated as the number of synonymous and nonsynonymous variants
per sequence in all 148 SNpc samples, 155 FC samples, and 7729
human mtDNA sequences and is represented as a percentage of the
total number of variants per group.
2.8. Statistical analysis
Variant counts and heteroplasmy mutation burden were quan-
tified and compared using Linux command line scripts (available on
request). Statistical comparisons were performed in SPSS (v15),
using data appropriate measurements detailed where appropriate.
All group-based test probabilities, that is, loci-specific mutational
burden testing in each tissue, were corrected by Bonferroni to
correct for multiple significance testing.
3. Results
Following strict QC, we compared the frequency of mtDNA
variation between PD cases and controls in the largest study of
mtDNA variation to date.
Stratifying variants by tissue- and variant-type identified a sig-
nificant difference in the mean heteroplasmic variant burden be-
tween cases and controls in both SNpc and FC (p ¼ 1.2  102 and
p ¼ 5.0  103, respectively; Fig 1C). Limiting to nonsynonomous
heteroplasmic variation and further stratifying by mtDNA locus
revealed a significant overrepresentation of PD cases harboring
MTCOX1, MTCOX2, and MTCYTB variants in SNpc and MTCYTB vari-
ants in FC tissue (Fig 1D and E). These variants were typically low
level (predominantly <10%) in both SNpc and FC of PD cases and
controls (Supplementary Fig. 1 and Supplementary Table 3); how-
ever, assessment of predicted functionality through established
pathogenicity scoring (Pereira et al., 2011) revealed significantly
higher scores when comparing “total mtDNA variation” (p ¼ 1.0 
102), MTCOX1 (p ¼ 1.0  104), MTCOX2 (p ¼ 2.0  103), andMTCYTB (p ¼ 1.0  104) in SNpc tissue between PD cases and
controls (Supplementary Fig. 2) an indication that these hetero-
plasmic variant burdens are potentially detrimental.
Heteroplasmic variation in MTCOX3 appears overrepresented in
control SNpc (Fig.1D) indicating either a, “protective effect” ormore
likely a cellular intolerance to further MTCOX3 mutation in PD
samples harboring already increasedMTCOX variation, a hypothesis
supported by observations in Alzheimer’s disease (Lu et al., 2010).
Unsurprisingly, heteroplasmic variation in the DLOOP accounted
for a large proportion of differential variation in both cases and
controls, a phenomenon reported in similar studies
(Supplementary Fig. 3) (Williams et al., 2013), and MTATP8,
MTND4L, and MTDN4 appear well-conserved in both PD cases and
controls, an indication of mutational intolerance in these particular
subunits and again similar to published data. However, we found no
significant difference in the distributions of displacement loop,
rRNA, or tRNA variants in either SNpc or FC when comparing PD
cases to controls.
With previous studies linking PD tomtDNA haplogroup (Hudson
et al., 2013, 2014), we correlated heteroplasmic variant frequency
with background mtDNA sequence, but failed to identify a link
when analyzing either PD cases or controls in either SNpc or FC
indicating no-predisposing link between mutation formation and
mtDNA sequence. In addition, and contrary to other studies (Simon
et al., 2004), we found no significant correlation to heteroplasmy
level or frequencies to either age (Supplementary Fig. 4), whichmay
be cohort selective (i.e., the age range is limited) and limited by the
low levels of heteroplasmy we identified, but is also supportive of a
recent hypothesis suggesting that heteroplasmic variation forma-
tion and expansion primarily occurs in the first half of life (Greaves
et al., 2014). Restricting the analysis to PD cases and correlating
heteroplasmic variant frequencies to age of onset failed to identify a
significant association (Supplementary Fig. 4).
Despite a high number of mtDNA variants, we were unable to
identify primary pathogenic mtDNA variants in either SNpc or FC,
identifying only alleles putatively associated with several complex
traits (Supplementary Table 1). We did identify a single SNpc case
harboring the MELAS variant m.3243A>G although this was at a
subclinical level (1.02%) and is likely a chance incidental finding.
Limiting to samples where both SNpc and FC tissuewas available
(cases ¼ 97 and controls ¼ 23) allowed the assessment somatic
mtDNA variation. Using FC tissue as ancestral mtDNA reference
sequence and SNpc as the vulnerable affected tissue allowed us to
identify 4 potential variant classes: (1) de-novo variants (present in
SNpc, but not FC); (2) somatic losses (present in FC, but not SNpc);
(3) negative-heteroplasmic shifts (a heteroplasmy decrease be-
tween FC to SNpc or DhetFC > SNpc); and (4) positive-
heteroplasmic-shifts (a heteroplasmy increase from FC to SNpc or
DhetFC < SNpc).
Post-QC analysis revealed a significantly increased frequency of
de novo mtDNA variants in PD cases compared to controls (p ¼
5.9  103). This variation appears predominantly, in line with our
previous data, as nonsynonomous variation in MTCOX1, MTCOX2,
and MTCYTB (Fig. 2).
Interestingly, further analysis revealed a significant over repre-
sentation of somatic-losses and negative-heteroplasmic shifts in
SNpc when comparing PD cases to controls (p ¼ 1.9  105 and
2.8  102, respectively; Fig. 2), indicating there is strong purifying
selection in the SNpc of PD cases, as variants are either removed or
heteroplasmy is lowered. Closer inspection of the variant types
reveals that PD cases are removing rRNA and synonomous, variants
at higher rates than controls; with nonsynonomous variation in
MTATP6 and MTCTYB significantly affected (Fig. 2).
Analysis of total positive-heteroplasmic shifts failed to show a
significant difference between PD cases and controls (p ¼ 1.1 
Fig. 1. The upper panel shows the comparative mean number of (A) total variants, (B) homoplasmic variants, and (C) heteroplasmic variants stratified by status and tissue origin;
where PD ¼ shaded boxes and controls ¼ unshaded boxes. Statistical comparison by Mann-Whitney confirmed a higher heteroplasmic mutational burden in PD patients in both SN
and FC (*p ¼ 0.012 and **p ¼ 0.005). The lower panel shows further stratification of heteroplasmic variant burden, limiting to nonsynonomous variants in SN (D) and FC (E) only;
where PD ¼ shaded boxes and controls ¼ unshaded boxes. Statistical comparison by Mann-Whitney confirmed a significant (P  0.0001, starred) overrepresentation of hetero-
plasmic nonsynonymous variants in PD in MTCOX1, MTCOX2 in SN, and MTCYTB in both SN and FC (error bars indicate 95% confidence intervals). Abbreviations: SN ¼ substantia
nigra; FC ¼ frontal cortex; PD, Parkinson’s disease; COX, cytochrome c oxidase; ATP, adenosine triphosphate.
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that PD cases have increased heteroplasmy levels in non-
synonomous variants, predominantly in MTCYTB (Fig. 2).
4. Discussion
The age-related accumulation of heteroplasmic variation is a
cardinal component of the biology of aging (Larsson, 2010), yet, the
differential spectra of heteroplasmy in human brain tissue and the
consequences for age-related disease have not been fully described.
Our data show that increased heteroplasmic mtDNA variation,
particularly in MTCOX1, MTCOX2, and MTCYTB, is a hallmark of
postmortem PD tissue; genetically supporting early observations
that cytochrome c oxidase (COX, complex-IV) activity is an impor-
tant component in PD (Gu et al., 1998; Kraytsberg et al., 2006; Rana
et al., 2000; Shinde and Pasupathy, 2006) and indicating that het-
eroplasmic variation likely contributes to the decreased level of COX
subunit expression seen in the brains of neurodegenerative patients(Aksenov et al., 1999). Contrary to this hypothesis, the variants we
identified were typically low level (predominantly <10%) in both
SNpc and FC of PD cases and controls raising the possibility that
either: (1) these variants are benign and unlikely to result in a
biochemical deficit or (2) they are deleterious and have contributed
to neuronal cell death in cells where they have clonally expanded.
The latter seems more likely, given the significantly different pre-
dicted pathogenicity seen between cases and controls; however,
functional experiments will be needed to fully investigate this.
Similar to previous studies (Stewart et al., 2008), we found a
decrease in the number of first and second codon variants
compared to third codon variants in both SNpc and FC when
analyzed collectively (Supplementary Fig. 5), suggestive of purify-
ing selection. However, when compared to population controls,
both SNpc and FC showed a significant overrepresentation of
nonsynonymous codon 1 variants (SNpc ¼ 0.04 and FC ¼ 0.04)
compared to the human sequences, further suggesting increased
overall mutagenesis in the brain.
Fig. 2. The left panel shows the comparative distribution of (A) de novo SNpc variants; (B) variants lost in SNpc compared to FC; (C) negative-heteroplasmic shifts (DhetFC > SNpc);
and (D) positive-heteroplasmic shifts (DhetFC < SNpc) between PD cases (shaded) and controls (unshaded) using Mann-Whitney nonparametric testing. The middle panel shows
the percentage breakdown by variant type, and the right panels shows the mtDNA locus distribution of identified heteroplasmic nonsynonymous variants, where * Pearson’s chi-
squared P  0.05 when comparing PD cases and controls. Abbreviations: SNpc, substantia nigra pars compacta; FC, frontal cortex; PD, Parkinson’s disease; mtDNA, mitochondrial
DNA; ATP, adenosine triphosphate.
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aging (Mizuno et al., 1989; Smigrodzki et al., 2004), we found
relatively few MTND* variants. One, m.12680 (MTND5) has been
previously reported in PD brains (Smigrodzki et al., 2004). This may
indicate that in fact complex I variation is not a component of PD or
may reflect the lack of remaining SNpc in postmortem, late-stage,
PD cases, where pathogenic MTND* variants have already resulted
in cell death (Cantuti-Castelvetri et al., 2005).
Somatic mutation analysis suggests that the SNpc of PD cases
undergoes strong purifying selection, particularly removing or
depleting nonsynonomous heteroplasmic variation when
compared tomatched FC tissue. However, our data suggests this is a
losing battle, as PD cases also show an increase in the formation of
de novo nonsynonomous MTND1, MTND2, MTCO2, MTCO3, and
MTCYTB variants in the SNpc compared to controls.
The identification of variants both lost and gained in SNpc
(when compared to FC) appears initially paradoxical, although it is
likely that this is either a product of end-stage PD; where cell death
has removed the causative variants leaving only the healthiest cells,
or it is a result of the “viscous cycle” of mutation formation seen
during the increased mitochondrial dysfunction seen in PD
(Swerdlow et al., 1996). The most likely explanation is a combina-
tion of both phenomena; as comparative pathogenicity scores of
somatic, nonsynonomous, heteroplasmic variation (Supplementary
Fig. 6) and an increased mutational burden in PD SNpc compared to
controls, indicate that detrimental mutation formation is super-
seding mutation loss. In addition, studies have shown that low-level heteroplasmic variants can escape the murine inheritance
bottle-neck and may impair brain development. The inclusion of
further tissue samples, such as tissue from nonectodermal lineages
could be used to investigate the origins of somatic mutation further,
although this tissue is not always readily available from brain tissue
banks.
Finally, we also recognize some study limitations. The avail-
ability of viable, nonpathological control, tissue limits the power of
the comparisons we can make. We have mitigated this in part,
studying a large cohort of PD cases and investigating the effects of
somatic mtDNA variation; however, replication of these findings in
an independent cohort is warranted.4.1. Conclusion
Here, using established NGS techniques, we show that hetero-
plasmic and somatic mtDNA variation is a hallmark of PD. Our data
indicate that the brain is in a state of mutational flux, both gaining
and losing mtDNA variation over time, but more importantly, our
study confirms the important role of age-related mtDNA point
mutation in the etiology of PD, moreover, by analyzing 2 distinct
brain regions, we are able to show that PD patient brains are more
vulnerable to mtDNA mutation overall. However, if the role of
mtDNA mutation is to be fully understood, replication of these
findings in an unrelated cohort and further investigation of the
functional role of this variation is recommended.
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